Annual EBIT
-$21.44 M
+$3.38 M+13.63%
December 31, 2023
Summary
- As of February 8, 2025, BCLI annual earnings before interest & taxes is -$21.44 million, with the most recent change of +$3.38 million (+13.63%) on December 31, 2023.
- During the last 3 years, BCLI annual EBIT has risen by +$10.24 million (+32.33%).
- BCLI annual EBIT is now -65462.69% below its all-time high of -$32.70 thousand, reached on March 31, 2002.
Performance
BCLI EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly EBIT
-$3.05 M
-$66.00 K-2.21%
September 30, 2024
Summary
- As of February 8, 2025, BCLI quarterly earnings before interest & taxes is -$3.05 million, with the most recent change of -$66.00 thousand (-2.21%) on September 30, 2024.
- Over the past year, BCLI quarterly EBIT has dropped by -$66.00 thousand (-2.21%).
- BCLI quarterly EBIT is now -1380.67% below its all-time high of $238.00 thousand, reached on December 31, 2017.
Performance
BCLI Quarterly EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM EBIT
-$13.31 M
+$2.99 M+18.33%
September 30, 2024
Summary
- As of February 8, 2025, BCLI TTM earnings before interest & taxes is -$13.31 million, with the most recent change of +$2.99 million (+18.33%) on September 30, 2024.
- Over the past year, BCLI TTM EBIT has increased by +$2.99 million (+18.33%).
- BCLI TTM EBIT is now -118721.43% below its all-time high of -$11.20 thousand, reached on June 30, 2002.
Performance
BCLI TTM EBIT Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
EBIT Formula
EBIT = Revenue − COGS − Operating Expenses
BCLI EBIT Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | +13.6% | -2.2% | +18.3% |
| 3 y3 years | +32.3% | -2.2% | +18.3% |
| 5 y5 years | -52.5% | -2.2% | +18.3% |
BCLI EBIT Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | at high | +13.6% | -23.2% | +59.9% | at high | +49.0% |
| 5 y | 5-year | at high | +32.3% | -23.2% | +73.5% | at high | +58.0% |
| alltime | all time | <-9999.0% | +32.3% | -1380.7% | +84.4% | <-9999.0% | +65.3% |
Brainstorm Cell Therapeutics EBIT History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$3.05 M(+2.2%) | -$13.31 M(-18.3%) |
| Jun 2024 | - | -$2.98 M(+20.5%) | -$16.30 M(-13.1%) |
| Mar 2024 | - | -$2.47 M(-48.5%) | -$18.76 M(-12.5%) |
| Dec 2023 | -$21.44 M(-13.6%) | -$4.80 M(-20.4%) | -$21.44 M(-0.5%) |
| Sep 2023 | - | -$6.04 M(+10.8%) | -$21.55 M(-3.6%) |
| Jun 2023 | - | -$5.45 M(+5.8%) | -$22.36 M(-8.7%) |
| Mar 2023 | - | -$5.15 M(+4.8%) | -$24.50 M(-1.3%) |
| Dec 2022 | -$24.82 M(+1.2%) | -$4.92 M(-28.2%) | -$24.82 M(-5.0%) |
| Sep 2022 | - | -$6.84 M(-9.9%) | -$26.12 M(+6.4%) |
| Jun 2022 | - | -$7.59 M(+38.6%) | -$24.55 M(+6.4%) |
| Mar 2022 | - | -$5.47 M(-11.9%) | -$23.09 M(-5.9%) |
| Dec 2021 | -$24.54 M(-22.6%) | -$6.21 M(+17.7%) | -$24.54 M(-17.7%) |
| Sep 2021 | - | -$5.28 M(-13.8%) | -$29.82 M(+2.7%) |
| Jun 2021 | - | -$6.12 M(-11.7%) | -$29.03 M(-4.2%) |
| Mar 2021 | - | -$6.93 M(-39.7%) | -$30.30 M(-4.4%) |
| Dec 2020 | -$31.68 M(+37.8%) | -$11.49 M(+156.2%) | -$31.68 M(+13.7%) |
| Sep 2020 | - | -$4.49 M(-39.4%) | -$27.86 M(-3.7%) |
| Jun 2020 | - | -$7.40 M(-10.9%) | -$28.92 M(+9.6%) |
| Mar 2020 | - | -$8.31 M(+8.4%) | -$26.38 M(+14.7%) |
| Dec 2019 | -$23.00 M(+63.6%) | -$7.67 M(+38.1%) | -$23.00 M(+10.7%) |
| Sep 2019 | - | -$5.55 M(+14.3%) | -$20.77 M(+12.6%) |
| Jun 2019 | - | -$4.86 M(-1.4%) | -$18.45 M(+10.6%) |
| Mar 2019 | - | -$4.93 M(-9.4%) | -$16.68 M(+18.6%) |
| Dec 2018 | -$14.06 M(+181.3%) | -$5.44 M(+68.2%) | -$14.06 M(+67.7%) |
| Sep 2018 | - | -$3.23 M(+4.7%) | -$8.39 M(+11.1%) |
| Jun 2018 | - | -$3.09 M(+33.8%) | -$7.55 M(+36.3%) |
| Mar 2018 | - | -$2.31 M(-1069.3%) | -$5.54 M(+10.7%) |
| Dec 2017 | -$5.00 M(-1.7%) | $238.00 K(-109.9%) | -$5.00 M(-15.1%) |
| Sep 2017 | - | -$2.39 M(+122.5%) | -$5.89 M(+14.7%) |
| Jun 2017 | - | -$1.07 M(-39.3%) | -$5.13 M(+1.8%) |
| Mar 2017 | - | -$1.77 M(+172.3%) | -$5.04 M(-0.8%) |
| Dec 2016 | -$5.08 M(-40.5%) | -$650.00 K(-60.3%) | -$5.08 M(-12.8%) |
| Sep 2016 | - | -$1.64 M(+66.6%) | -$5.83 M(-13.8%) |
| Jun 2016 | - | -$983.00 K(-45.8%) | -$6.76 M(-16.9%) |
| Mar 2016 | - | -$1.81 M(+29.7%) | -$8.14 M(-4.6%) |
| Dec 2015 | -$8.54 M(+15.0%) | -$1.40 M(-45.7%) | -$8.54 M(-12.9%) |
| Sep 2015 | - | -$2.57 M(+8.8%) | -$9.80 M(+1.5%) |
| Jun 2015 | - | -$2.36 M(+7.2%) | -$9.66 M(+12.4%) |
| Mar 2015 | - | -$2.21 M(-17.3%) | -$8.60 M(+15.8%) |
| Dec 2014 | -$7.42 M(+47.2%) | -$2.67 M(+9.7%) | -$7.42 M(+20.5%) |
| Sep 2014 | - | -$2.43 M(+87.8%) | -$6.16 M(+28.2%) |
| Jun 2014 | - | -$1.29 M(+25.5%) | -$4.80 M(-3.8%) |
| Mar 2014 | - | -$1.03 M(-26.4%) | -$4.99 M(-1.0%) |
| Dec 2013 | -$5.04 M | -$1.40 M(+30.2%) | -$5.04 M(+17.9%) |
| Sep 2013 | - | -$1.08 M(-27.5%) | -$4.28 M(-2.2%) |
| Jun 2013 | - | -$1.49 M(+37.4%) | -$4.37 M(+17.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Mar 2013 | - | -$1.08 M(+70.2%) | -$3.72 M(+5.7%) |
| Dec 2012 | -$3.52 M(-9.7%) | -$635.00 K(-45.8%) | -$3.52 M(-17.9%) |
| Sep 2012 | - | -$1.17 M(+40.7%) | -$4.29 M(+11.2%) |
| Jun 2012 | - | -$833.00 K(-5.2%) | -$3.85 M(-13.1%) |
| Mar 2012 | - | -$879.00 K(-37.3%) | -$4.44 M(+8.6%) |
| Dec 2011 | -$3.89 M(+62.3%) | -$1.40 M(+89.6%) | -$4.09 M(+26.8%) |
| Sep 2011 | - | -$740.00 K(-47.7%) | -$3.22 M(+3.4%) |
| Jun 2011 | - | -$1.42 M(+168.0%) | -$3.12 M(+34.5%) |
| Mar 2011 | - | -$528.00 K(-2.2%) | -$2.32 M(-3.4%) |
| Dec 2010 | -$2.40 M(+37.1%) | -$540.00 K(-15.0%) | -$2.40 M(+22.9%) |
| Sep 2010 | - | -$635.00 K(+3.1%) | -$1.95 M(+2.2%) |
| Jun 2010 | - | -$616.00 K(+1.1%) | -$1.91 M(+5.1%) |
| Mar 2010 | - | -$609.00 K(+554.8%) | -$1.82 M(+3.9%) |
| Dec 2009 | -$1.75 M(-46.5%) | -$93.00 K(-84.3%) | -$1.75 M(-25.0%) |
| Sep 2009 | - | -$593.00 K(+13.2%) | -$2.33 M(-4.3%) |
| Jun 2009 | - | -$524.00 K(-3.0%) | -$2.44 M(-8.9%) |
| Mar 2009 | - | -$540.00 K(-20.0%) | -$2.67 M(-18.2%) |
| Dec 2008 | -$3.27 M(-33.5%) | -$675.00 K(-3.2%) | -$3.27 M(+2.6%) |
| Sep 2008 | - | -$697.00 K(-8.5%) | -$3.19 M(-19.3%) |
| Jun 2008 | - | -$762.00 K(-32.8%) | -$3.95 M(-2.5%) |
| Mar 2008 | - | -$1.13 M(+91.2%) | -$4.05 M(-4.8%) |
| Dec 2007 | -$4.92 M(+70.5%) | -$593.00 K(-59.3%) | -$4.25 M(+16.2%) |
| Sep 2007 | - | -$1.46 M(+68.8%) | -$3.66 M(+18.3%) |
| Jun 2007 | - | -$863.00 K(-35.5%) | -$3.09 M(+1.0%) |
| Mar 2007 | - | -$1.34 M(+50.4%) | -$3.06 M(-6.2%) |
| Dec 2006 | -$2.88 M(-12.7%) | - | - |
| Sep 2006 | - | -$890.00 K(+6.9%) | -$3.26 M(-4.1%) |
| Jun 2006 | - | -$832.40 K(+33.3%) | -$3.40 M(+3.0%) |
| Mar 2006 | - | -$624.30 K(-31.8%) | -$3.30 M(-0.7%) |
| Mar 2006 | -$3.30 M(-82.5%) | - | - |
| Dec 2005 | - | -$915.00 K(-11.1%) | -$3.32 M(-82.5%) |
| Sep 2005 | - | -$1.03 M(+40.4%) | -$19.01 M(-2.8%) |
| Jun 2005 | - | -$732.80 K(+13.2%) | -$19.56 M(-49.1%) |
| Mar 2005 | -$18.83 M(>+9900.0%) | -$647.60 K(-96.1%) | -$38.39 M(+1.6%) |
| Dec 2004 | - | -$16.60 M(+954.4%) | -$37.78 M(+78.3%) |
| Sep 2004 | - | -$1.57 M(-92.0%) | -$21.19 M(+8.0%) |
| Jun 2004 | - | -$19.57 M(>+9900.0%) | -$19.63 M(>+9900.0%) |
| Mar 2004 | -$73.30 K(+56.6%) | -$35.80 K(+145.2%) | -$73.30 K(+82.8%) |
| Dec 2003 | - | -$14.60 K(+32.7%) | -$40.10 K(-14.3%) |
| Sep 2003 | - | -$11.00 K(-7.6%) | -$46.80 K(-1.5%) |
| Jun 2003 | - | -$11.90 K(+357.7%) | -$47.50 K(+1.5%) |
| Mar 2003 | -$46.80 K(+43.1%) | -$2600.00(-87.8%) | -$46.80 K(+5.9%) |
| Dec 2002 | - | -$21.30 K(+82.1%) | -$44.20 K(+93.0%) |
| Sep 2002 | - | -$11.70 K(+4.5%) | -$22.90 K(+104.5%) |
| Jun 2002 | - | -$11.20 K | -$11.20 K |
| Mar 2002 | -$32.70 K | - | - |
FAQ
- What is Brainstorm Cell Therapeutics annual earnings before interest & taxes?
- What is the all time high annual EBIT for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics annual EBIT year-on-year change?
- What is Brainstorm Cell Therapeutics quarterly earnings before interest & taxes?
- What is the all time high quarterly EBIT for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics quarterly EBIT year-on-year change?
- What is Brainstorm Cell Therapeutics TTM earnings before interest & taxes?
- What is the all time high TTM EBIT for Brainstorm Cell Therapeutics?
- What is Brainstorm Cell Therapeutics TTM EBIT year-on-year change?
What is Brainstorm Cell Therapeutics annual earnings before interest & taxes?
The current annual EBIT of BCLI is -$21.44 M
What is the all time high annual EBIT for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high annual earnings before interest & taxes is -$32.70 K
What is Brainstorm Cell Therapeutics annual EBIT year-on-year change?
Over the past year, BCLI annual earnings before interest & taxes has changed by +$3.38 M (+13.63%)
What is Brainstorm Cell Therapeutics quarterly earnings before interest & taxes?
The current quarterly EBIT of BCLI is -$3.05 M
What is the all time high quarterly EBIT for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high quarterly earnings before interest & taxes is $238.00 K
What is Brainstorm Cell Therapeutics quarterly EBIT year-on-year change?
Over the past year, BCLI quarterly earnings before interest & taxes has changed by -$66.00 K (-2.21%)
What is Brainstorm Cell Therapeutics TTM earnings before interest & taxes?
The current TTM EBIT of BCLI is -$13.31 M
What is the all time high TTM EBIT for Brainstorm Cell Therapeutics?
Brainstorm Cell Therapeutics all-time high TTM earnings before interest & taxes is -$11.20 K
What is Brainstorm Cell Therapeutics TTM EBIT year-on-year change?
Over the past year, BCLI TTM earnings before interest & taxes has changed by +$2.99 M (+18.33%)